ArticleInternational urology and nephrology2025
Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European study.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo evaluate whether adherence to specific quality criteria in the management of T1 non-muscle-invasive bladder cancer (NMIBC) undergoing second-look transurethral resection of bladder tumor (TURBT) leads to improved oncological outcomes. MATERIALS AND
methodsA retrospective multicenter study included patients diagnosed between 2015 and 2021 with high or very-high-risk a NMIBC after initial TURBT, followed by second-look TURBT and Bacillus Calmette-Guérin (BCG) adjuvant therapy. Key management steps assessed included enhanced tumor visualization, complete resection, timing of second look, detrusor muscle presence in specimens, and adequate BCG therapy. The primary endpoint was bladder recurrence-free survival (RFS), analyzed using Kaplan-Meier curves and Cox regression models.
resultsAmong 226 patients included, the median age was 73(65-79) years, and 49 were classified in the very high-risk group (22%). Second-look TURBT was performed with a median delay of 8 (6-10) weeks. Factors significantly impacting 3-year RFS included adequate BCG exposure (HR = 0.55; 95% CI 0.32-0.93; p = 0.03) and the presence of residual tumor at second-look TURBT (HR = 2.55; 95% CI 1.48-4.39; p < 0.001). Neither the use of photodynamic diagnostics nor timing beyond 6 weeks for second-look TURBT significantly influenced outcomes (p > 0.05).
conclusionsIn T1 NMIBC, adequate BCG therapy and absence of residual tumor at second-look TURBT are the primary predictors of 3-year RFS. These findings emphasize the importance of quality management in TURBT procedures and patient treatment.
Indexed as
Identifiers
39934553What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.